GSK-256066-Trifluoroacetate-GSK256066-2-2-2-trifluoroacetic-acid-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGSK 256066 TrifluoroacetateCat. No.: HY-70069CAS No.: 1415560-64-3Synonyms: GSK256066 (2,2,2-trifluoroacetic acid)分式: CHFNOS分量: 632.61作靶点: Phosphodiesterase (PDE)作通路: Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn

2、 solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (79.04 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.5808 mL 7.9038 mL 15.8075 mL5 mM 0.3162 mL 1.5808 mL 3.1615 mL10 mM 0.1581 mL 0.7904 mL 1.5808 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选

3、择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 3.25 mg/mL (5.14 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 3.25 mg/mL (5.14 mM); Clea

4、r solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 GSK 256066 Trifluoroacetate种选择性、亲和的 PDE 抑制剂，抑制 PDE4B 的 IC50 值为 3.2 pM。被开发于治疗慢性阻塞性肺病 1。IC50 & Target IC50: 3.2 pM (PDE4B) 1体外研究 GSK 256066 Trifluoroacetate is an exceptionally high-affinity inhibitor of PDE4 designed fo

5、r inhaledadministration 1.GSK 256066 Trifluoroacetate is highly selective for PDE4, with 380,000-fold versus PDE1/2/3/5/6 and2500-fold against PDE7, and inhibits PDE4 isoforms A-D with equal affinity 1.GSK 256066 Trifluoroacetate inhibits tumor necrosis factor production by lipopolysaccharide (LPS)-

6、stimulated human peripheral blood monocytes with IC50 of 0.01 nM 1.体内研究 GSK 256066 Trifluoroacetate (0.3-100 g/kg; intratracheally) inhibits the eosinophil number increased in thebronchoalveolar lavage (BAL) in a dose-dependent fashion, in lipopolysaccharide (LPS)- and ovalbumin(OVA)-induced acute p

7、ulmonary inflammation rat models. 2.GSK 256066 Trifluoroacetate inhibits LPS-induced pulmonary neutrophilia, and no emetic episodes areobserved in ferrets 2.Animal Model: Male Brown Norway rats(180-200 g) 2Dosage: 0.3-100 g/kgAdministration: Intratracheally; 30 minutes before and 6 hours after ovalb

8、umin challengeResult: Inhibited the increase in eosinophil number in the BAL in a dose-dependent fashion.REFERENCES1. Tralau-Stewart CJ, et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable foradministration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther, 2011, 337(1), 145-154.2. Nials AT, et al. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther,2011, 337(1), 137-144.McePdfHeightCaution: Product has not been fully validated for medical a